BRPI0610644B8 - composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável. - Google Patents

composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.

Info

Publication number
BRPI0610644B8
BRPI0610644B8 BRPI0610644A BRPI0610644A BRPI0610644B8 BR PI0610644 B8 BRPI0610644 B8 BR PI0610644B8 BR PI0610644 A BRPI0610644 A BR PI0610644A BR PI0610644 A BRPI0610644 A BR PI0610644A BR PI0610644 B8 BRPI0610644 B8 BR PI0610644B8
Authority
BR
Brazil
Prior art keywords
compound
diluent
pharmaceutically acceptable
pharmaceutical composition
acceptable carrier
Prior art date
Application number
BRPI0610644A
Other languages
English (en)
Portuguese (pt)
Inventor
J Bergeron Raymond
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36676582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0610644(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Florida filed Critical Univ Florida
Publication of BRPI0610644A2 publication Critical patent/BRPI0610644A2/pt
Publication of BRPI0610644B1 publication Critical patent/BRPI0610644B1/pt
Publication of BRPI0610644B8 publication Critical patent/BRPI0610644B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
BRPI0610644A 2005-04-04 2006-03-22 composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável. BRPI0610644B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66804505P 2005-04-04 2005-04-04
US60/668,05 2005-04-04
US60/668,045 2005-04-04
PCT/US2006/010945 WO2006107626A1 (en) 2005-04-04 2006-03-22 Desferrithiocin polyether analogues

Publications (3)

Publication Number Publication Date
BRPI0610644A2 BRPI0610644A2 (pt) 2010-07-13
BRPI0610644B1 BRPI0610644B1 (pt) 2020-09-29
BRPI0610644B8 true BRPI0610644B8 (pt) 2021-05-25

Family

ID=36676582

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610644A BRPI0610644B8 (pt) 2005-04-04 2006-03-22 composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.

Country Status (14)

Country Link
US (6) US8278458B2 (OSRAM)
EP (2) EP1866296B1 (OSRAM)
JP (3) JP5202299B2 (OSRAM)
CN (1) CN101189216B (OSRAM)
AU (1) AU2006232929B9 (OSRAM)
BR (1) BRPI0610644B8 (OSRAM)
CA (1) CA2603385C (OSRAM)
CY (1) CY1119002T1 (OSRAM)
DK (2) DK1866296T3 (OSRAM)
ES (2) ES2614086T3 (OSRAM)
MX (1) MX2007012226A (OSRAM)
PL (2) PL3190106T3 (OSRAM)
TR (1) TR201910900T4 (OSRAM)
WO (1) WO2006107626A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
DK1866296T3 (en) * 2005-04-04 2017-02-13 Univ Florida DESFERRITHIOCINPOLYETHER-ANALOGS
WO2008130395A2 (en) * 2006-12-12 2008-10-30 University Of Florida Desferrithiocin analogue actinide decorporation agents
BRPI0809077A2 (pt) * 2007-03-15 2014-09-09 Univ Florida Res Foudantion Inc Análogos de poliéter de desferritiocina
WO2010009120A2 (en) * 2008-07-14 2010-01-21 Ferrokin Biosciences, Inc. Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
WO2011017054A2 (en) * 2009-07-27 2011-02-10 Ferrokin Biosciences, Inc. Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
US20120184586A1 (en) * 2009-08-25 2012-07-19 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof
AU2011248158A1 (en) * 2010-05-04 2012-12-20 Ferrokin Biosciences, Inc. Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
EP2787994A4 (en) 2011-12-09 2015-08-26 Ferrokin Biosciences Inc ORAL FORMULATIONS FOR TREATING METAL OVERLOAD
JP6539046B2 (ja) 2011-12-16 2019-07-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ４’−デスフェリチオシン類似体の使用
CA2905026A1 (en) 2013-03-15 2014-09-18 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
EP3071201A4 (en) * 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
SG11201610906XA (en) * 2014-07-18 2017-02-27 Applied Materials Inc Additive manufacturing with laser and plasma
CN107708693A (zh) * 2015-04-27 2018-02-16 佛罗里达大学研究基金会 代谢程序化的金属螯合剂及其用途
US10982136B2 (en) 2016-02-26 2021-04-20 The Regents Of The University Of California Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters
EP3493801B1 (en) 2016-08-05 2025-12-31 Abfero Pharmaceuticals, Inc. Dosage regimens with (S)-4,5-dihydro-2-[2-hydroxy-4-(3,6-dioxaheptyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid for use in the treatment of iron overload
WO2018044812A2 (en) 2016-08-29 2018-03-08 Fred Hutchinson Cancer Research Center Chelating platform for delivery of radionuclides
WO2018048812A1 (en) * 2016-09-06 2018-03-15 The Regents Of The University Of California Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
JP7323737B2 (ja) 2016-09-29 2023-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 液－液抽出による金属イオンの分離
WO2018063638A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Chelating molecules

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274207A (en) * 1966-09-20 Processes for preparing thiazole carboxylic acids
US3809754A (en) * 1968-12-31 1974-05-07 Medial De Toledo & Cie Method of treating diseases of the mucous membrane using compounds of a thiazolidine carboxylic acid and pharmaceutical preparations thereof
US3882110A (en) * 1969-06-11 1975-05-06 Roussel Uclaf Novel 2-alkyl-5-thiazole-carboxylic acid derivatives
DE2045818A1 (de) 1969-09-17 1971-04-08 Godo Shusei Kabushiki Kaisha, Tokio Aeruginoinsäure und Verfahren zu ihrer Herstellung
FR2062120A5 (OSRAM) 1969-10-10 1971-06-25 Messier Fa
FR2141526B1 (OSRAM) 1971-06-14 1975-05-30 Roussel Uclaf
DE2245560A1 (de) 1972-09-16 1974-03-21 Basf Ag Verfahren zur herstellung von 4alkoxycarbonyl-2-thiazolinen
AU528115B2 (en) * 1978-04-08 1983-04-14 Santen Pharmaceutical Co. Ltd. Antihypertensive 4-thiazolidine/carboxylic acids
CS205217B1 (cs) 1979-04-05 1981-05-29 Zdenek Vitamvas Dozimetr ionizujícího záření
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
DE3002989A1 (de) * 1980-01-29 1981-07-30 Hoechst Ag, 6000 Frankfurt Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels
DE3170401D1 (en) * 1980-07-28 1985-06-13 Ciba Geigy Ag Triazoline derivatives and processes for their preparation
ZA815129B (en) 1980-07-28 1982-07-28 Ciba Geigy Ag Thiazoline derivatives and processes for their manufacture
JPS5772975A (en) * 1980-10-24 1982-05-07 Kureha Chem Ind Co Ltd 2-substituted phenylthiazole derviative, and medicine for peptic ulcer containing said derivative as active component
US4367233A (en) * 1981-10-02 1983-01-04 American Home Products Corporation Inhibitors of mammalian collagenase
WO1986003677A1 (en) * 1984-12-18 1986-07-03 David Rubin Anti-tumor compositions containing the reaction product of a cytotoxic aldehyde with penicillamine and method of use thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
HU200177B (en) * 1985-06-18 1990-04-28 Biogal Gyogyszergyar Process for producing thiazolidinecarboxylic acids and pharmaceutical compositions comprising such compounds
US4736060A (en) * 1985-08-06 1988-04-05 Nippon Rikagakuyakuhin Co., Ltd. Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl) ethylamine
EP0214101A3 (de) 1985-09-03 1989-05-31 Ciba-Geigy Ag Verwendung von Eisen(III)-Chelatoren vom Typ Desferrioxamin B und Desferriferrithiocin zur Behandlung von Malaria
EP0214933A3 (de) 1985-09-03 1989-05-24 Ciba-Geigy Ag Kombinationspräparate zur Behandlung von Malaria
JPS62142168A (ja) * 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
DE3621540A1 (de) 1986-06-27 1988-01-07 Basf Ag Chinolinderivate, verfahren zu ihrer herstellung, diese enthaltende mikrobizide und ihre verwendung zur bekaempfung von bakterien und pilzen
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE3735757A1 (de) * 1987-10-22 1989-05-03 Degussa Optisch aktive salze aus einem substituierten thiazolidin-4-carboxylat und 3-chlor-2-hydroxypropyltrimethylammonium, deren herstellung und verwendung
ES2047149T3 (es) 1988-01-20 1994-02-16 Ciba Geigy Ag Procedimiento para la obtencion de compuestos complejos.
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
GB8826035D0 (en) * 1988-11-07 1988-12-14 Ici Plc Herbicidal compositions
US5182402A (en) * 1988-11-07 1993-01-26 Imperial Chemical Industries Plc Herbicidal compositions
US5106992A (en) * 1989-07-28 1992-04-21 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
NL9001955A (nl) * 1990-09-05 1992-04-01 Cedona Pharm Bv Nieuwe thiazolidinederivaten.
US5393777A (en) * 1990-11-15 1995-02-28 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Deferration using anguibactin siderophore
CA2396738C (en) * 1990-11-30 2006-08-29 Masatoshi Chihiro Thiazole derivatives as active superoxide radical inhibitors
JP2725886B2 (ja) 1990-11-30 1998-03-11 帝人株式会社 ２―アリールチアゾール誘導体及びその医薬組成物
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
FR2677021B1 (fr) * 1991-05-31 1993-10-01 Upsa Laboratoires Nouveaux derives de thiazole antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
AU5602594A (en) 1992-11-16 1994-06-08 University Of Florida Research Foundation, Inc. 2-(pyrid-2'-yl)-2-thiazoline-4(s)-carboxylic acid derivatives
US5840739A (en) 1992-11-16 1998-11-24 University Of Florida Research Foundation, Inc. Thiazoline acid derivatives
DE4301356A1 (de) * 1993-01-20 1994-07-21 Basf Ag Verfahren zur Herstellung von 2-Alkyl-4-fluormethyl-thiazolcarbonsäure-alkylestern
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
FR2749583B1 (fr) * 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
US20020049316A1 (en) * 1997-04-29 2002-04-25 Halbert Stacie Marie Protease inhibitors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6373912B1 (en) * 1997-06-16 2002-04-16 Legerity, Inc. Phase-locked loop arrangement with fast lock mode
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
CA2319255C (en) * 1998-02-04 2010-01-26 University Of Florida Research Foundation, Inc. Pharmaceuticals comprising n,n'-bis(2- hydroxybenzyl) ethylenediamine-n, n'-diacetic acid for iron chelating therapy
MA26618A1 (fr) 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
US6147070A (en) * 1998-06-05 2000-11-14 Facchini; Francesco Methods and compositions for controlling iron stores to treat and cure disease states
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
US6159983A (en) * 1998-09-18 2000-12-12 University Of Florida Method and composition for treatment of inflammatory bowel disease
CN1585639A (zh) 1998-09-21 2005-02-23 佛罗里达大学研究基金会 抗疟疾制剂
US6251927B1 (en) * 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
US7160855B2 (en) 2002-03-14 2007-01-09 Children's Hospital & Research Center At Oakland Enhancement of iron chelation therapy
US20040044220A1 (en) 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
WO2004017959A2 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
CA2538159A1 (en) * 2003-09-09 2005-03-17 University Of Florida Research Foundation, Inc. Polyamine-metal chelator conjugates
EP1819334A1 (en) 2004-11-19 2007-08-22 Shiva Biomedical, LLC Methods of treating erythropoietin-resistance
DK1866296T3 (en) 2005-04-04 2017-02-13 Univ Florida DESFERRITHIOCINPOLYETHER-ANALOGS
US20080194518A1 (en) 2005-12-23 2008-08-14 MOOKERJEE Pradip Antimicrobial Compositions
CN101129381B (zh) 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
WO2008130395A2 (en) 2006-12-12 2008-10-30 University Of Florida Desferrithiocin analogue actinide decorporation agents
BRPI0809077A2 (pt) 2007-03-15 2014-09-09 Univ Florida Res Foudantion Inc Análogos de poliéter de desferritiocina
FR2922210A1 (fr) 2007-10-11 2009-04-17 Univ Louis Pasteur Etablisseme Nouveaux composes, preparation et utilisations
WO2010009120A2 (en) 2008-07-14 2010-01-21 Ferrokin Biosciences, Inc. Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
PL385765A1 (pl) 2008-07-28 2010-02-01 Maciej Żurek Sposób sterowania łopatą napędową względem kierunku wiatru, zwłaszcza w silniku wiatrowym i wodnym o osi prostopadłej do kierunku wiatru oraz silnik wiatrowy o osi prostopadłej do kierunku wiatru z łopatą napędową sterowaną względem kierunku wiatru
WO2011017054A2 (en) 2009-07-27 2011-02-10 Ferrokin Biosciences, Inc. Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
US20120184586A1 (en) 2009-08-25 2012-07-19 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof
AU2011248158A1 (en) 2010-05-04 2012-12-20 Ferrokin Biosciences, Inc. Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
WO2012027794A2 (en) 2010-09-01 2012-03-08 The Mental Health Research Institute Of Victoria Method of treatment and agents useful for same
JP6539046B2 (ja) 2011-12-16 2019-07-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ４’−デスフェリチオシン類似体の使用
US20140323534A1 (en) 2011-12-16 2014-10-30 University Of Florida Research Foundation, Inc. Uses of 3'-desferrithiocin analogs
WO2014134701A1 (en) 2013-03-07 2014-09-12 Kane Biotech Inc. Antimicrobial-antibiofilm compositions and methods of use thereof
EP3071201A4 (en) 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof

Also Published As

Publication number Publication date
US9567309B2 (en) 2017-02-14
CN101189216A (zh) 2008-05-28
AU2006232929B2 (en) 2009-11-05
US8278458B2 (en) 2012-10-02
US9096553B2 (en) 2015-08-04
US20130030028A1 (en) 2013-01-31
EP3190106B1 (en) 2019-05-08
DK3190106T3 (da) 2019-07-15
WO2006107626A1 (en) 2006-10-12
CA2603385C (en) 2014-07-15
EP1866296A1 (en) 2007-12-19
PL3190106T3 (pl) 2019-10-31
TR201910900T4 (tr) 2019-08-21
AU2006232929B9 (en) 2009-12-17
US20140235680A1 (en) 2014-08-21
ES2732625T3 (es) 2019-11-25
CA2603385A1 (en) 2006-10-12
JP2012131814A (ja) 2012-07-12
ES2614086T3 (es) 2017-05-29
JP5202299B2 (ja) 2013-06-05
PL1866296T3 (pl) 2017-05-31
BRPI0610644A2 (pt) 2010-07-13
JP2015145403A (ja) 2015-08-13
CY1119002T1 (el) 2018-01-10
US9994535B2 (en) 2018-06-12
US20170217912A1 (en) 2017-08-03
BRPI0610644B1 (pt) 2020-09-29
EP1866296B1 (en) 2016-11-02
US8722899B2 (en) 2014-05-13
US20150336911A1 (en) 2015-11-26
DK1866296T3 (en) 2017-02-13
EP3190106A1 (en) 2017-07-12
JP2008536833A (ja) 2008-09-11
MX2007012226A (es) 2007-12-10
AU2006232929A1 (en) 2006-10-12
CN101189216B (zh) 2011-10-19
US20080214630A1 (en) 2008-09-04
JP5771546B2 (ja) 2015-09-02
US20180290990A1 (en) 2018-10-11
JP6178816B2 (ja) 2017-08-09

Similar Documents

Publication Publication Date Title
BRPI0610644B8 (pt) composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
ATE433447T1 (de) Pyrimiidinverbindungen
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
CY1110900T1 (el) Χημικες ενωσεις
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
TW200800963A (en) Chemical compounds
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
SE0403006D0 (sv) New compounds
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
WO2006089871A3 (en) Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer
PL1831239T3 (pl) Sposób wytwarzania gamma-laktonu kwasu 17-hydroksy-6 beta, 7 beta,15 beta, 16 beta-bismetyleno-17 alpha-pregn-4-en-3-ono-21-karboksylowego i związki pośrednie kluczowe dla tego sposobu
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
CA2585802A1 (en) Industrial process for the preparation of 17-hydroxy-6.beta.,7.beta.;15.beta.,16.beta.-bismethylene-3-oxo-17.alpha.pregn-4-ene-21-carboxylic acid.gamma.-lactone and key-intermediates for this process
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
WO2006080043A3 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
WO2007059356A3 (en) Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/03/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF